FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin

    NEXT STORY
    Novartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide
    PREV STORY
    Teleflex Incorporated Announces Worldwide Voluntary Recall of COMFORT FLO® Humidification System
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Biomica, Evogene’s Newly Established Subsidiary, Announces Therapeutic Areas of Focus

    author_avatar
    NASDAQ Market News

    AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA

    author_avatar
    NASDAQ Market News

    Basilea’s antifungal CRESEMBA(r) (isavuconazole) launched in Italy

    BASEL, Switzerland, June 27, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announces ...

    author_avatar
    NASDAQ Market News